Impaired adult olfactory bulb neurogenesis in the R6/2 mouse model of Huntington's disease by Kohl, Zacharias et al.
RESEARCH ARTICLE Open Access
Impaired adult olfactory bulb neurogenesis in
the R6/2 mouse model of Huntington’s disease
Zacharias Kohl
1, Martin Regensburger
2, Robert Aigner
1, Mahesh Kandasamy
2,3, Beate Winner
2,4, Ludwig Aigner
3,
Jürgen Winkler
1*
Abstract
Background: Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder linked to expanded
CAG-triplet nucleotide repeats within the huntingtin gene. Intracellular huntingtin aggregates are present in
neurons of distinct brain areas, among them regions of adult neurogenesis including the hippocampus and the
subventricular zone/olfactory bulb system. Previously, reduced hippocampal neurogenesis has been detected in
transgenic rodent models of HD. Therefore, we hypothesized that mutant huntingtin also affects newly generated
neurons derived from the subventricular zone of adult R6/2 HD mice.
Results: We observed a redirection of immature neuroblasts towards the striatum, however failed to detect new
mature neurons. We further analyzed adult neurogenesis in the granular cell layer and the glomerular layer of the
olfactory bulb, the physiological target region of subventricular zone-derived neuroblasts. Using bromodeoxyuridine
to label proliferating cells, we observed in both neurogenic regions of the olfactory bulb a reduction in newly
generated neurons.
Conclusion: These findings suggest that the striatal environment, severely affected in R6/2 mice, is capable of
attracting neuroblasts, however this region fails to provide sufficient signals for neuronal maturation. Moreover, in
transgenic R6/2 animals, the hostile huntingtin-associated microenvironment in the olfactory bulb interferes with
the survival and integration of new mature neurons. Taken together, endogenous cell repair strategies in HD may
require additional factors for the differentiation and survival of newly generated neurons both in neurogenic and
non-neurogenic regions.
Background
Huntington’s disease (HD) is a devastating autosomal
dominant hereditary neurodegenerative disease caused by
a CAG trinucleotide repeat expansion within the hun-
tingtin gene encoding an extended polyglutamine tract in
the huntingtin (htt) protein [1]. The progressive clinical
phenotype consists of involuntary choreic movements,
cognitive decline and psychiatric symptoms (reviewed in
[2]). Impaired olfactory function was also observed in
patients as well as presymptomatic gene carriers [3,4].
Emerging evidence suggests that mutant htt leads to
s e l e c t i v en e u r o n a ld a m a g eb yag a i no ft o x i cf u n c t i o n
inducing neuronal loss and gliosis predominantly in the
neostriatum and the cortex (reviewed in [5]).
The presence of neural stem cells in the adult central
nervous system (CNS) has been widely described both
in rodents and in humans (reviewed in [6]). In adult
mammals these cells are present in neurogenic regions
of the CNS, the subventricular zone (SVZ) of the lateral
ventricle wall and the dentate gyrus (DG) of the hippo-
campus. New cells are continuously generated in the
SVZ [7,8] and physiologically migrate via the rostral
migratory stream (RMS) to the olfactory bulb (OB)
[9,10]. Here they mainly differentiate into GABA-ergic
interneurons in the granular cell layer (GCL) or to a
lesser extent in the glomerular layer (GLOM), and func-
tionally integrate [11,12]. New GLOM neurons are
further subdivided based on their immunoreactivity
against tyrosine hydroxylase (TH), calbindin or calreti-
nin [13]. Neurogenesis in the OB is a life long phenom-
enon in the mammalian brain, leading to an increase in
the total number of neurons in the GLOM, while the
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balanced by continuous cell death [14]. Importantly,
neurogenesis in the adult CNS can be modulated by var-
ious molecular and environmental factors, in part acting
differentially on both neurogenic regions [6]. The stimu-
lation of this endogenous pool of immature neurons
may be a useful tool for a cell-based therapeutic
approach in neurodegenerative disorders [15].
In transgenic animal models of HD impaired adult
neurogenesis has been described in the DG of the hip-
pocampus [16,17], which could be partially restored by
environmental stimuli or antidepressants [18,19]. In
contrast, the proliferation of neural stem cells in the
SVZ is not affected in transgenic HD mouse models
[20,21]. The R6/2 HD mouse model carries exon 1 of
the human HD gene with an expanded CAG trinucleo-
tide repeat strand (130-150 CAG repeats; [22]) and exhi-
bits decreased striatal and total brain size, ubiquitinated
nuclear and cytoplasmic inclusion bodies [23], and pro-
gressive motor and cognitive deficits [24]. These mice
have an early onset of symptoms associated with a fast
progression and a limited life span of approximately 12
to 17 weeks, depending on the colony (reviewed in [25]).
To further rule out the impact of mutant htt on the
endogenous generation of new neurons we investigated
the SVZ/OB system in the R6/2 mouse model and ana-
lyzed the survival and differentiation of SVZ-derived
new neurons migrating towards their physiological tar-
get region, the OB, and to the adjacent severely affected
striatum.
Results
Aggregates of mutant huntingtin appear in mature
neurons, but not in neuroblasts in R6/2 mice
To determine whether aggregates of mutant htt were
present in the SVZ/OB (Fig. 1E), we used an a-hunting-
t i na n t i b o d ys p e c i f i cf o rt h eN - t e r m i n u so fh u m a n
mutant htt with a repeat expansion > 82 repeats
(MAB5374; [26]). We detected intranuclear immunor-
eactivity in some mature calretinin-expressing neurons
of both the GCL and the GLOM (Fig. 1I,J) and in TH-
expressing neurons of the GLOM (Fig. 1K). In contrast,
mutant htt was not detected in doublecortin (DCX)-
expressing neuroblasts of R6/2 animals in the GCL and
the GLOM of the OB (Fig. 1G, H), or in migrating DCX
positive neuroblasts in the RMS (Fig. 1F) and the SVZ
( F i g .1 C ) .B e s i d e st h eD C Xe x pressing SVZ neuroblasts
(or A cells) neither glial fibrillary acidic protein (GFAP)
expressing B cells (Fig. 1 ) nor epidermal growth factor
(EGF)-receptor expressing C cells (Fig. 1) showed intra-
nuclear immunoreactivity for htt aggregates. In contrast,
mature neurons of the adjacent striatum expressing
dopamine- and cAMP-regulated phosphoprotein-32
(DARPP-32) contained aggregates of htt (Fig. 1D). No
immunoreactivity of mutant human htt was observed in
the SVZ/OB of WT mice (data not shown).
Increased migration of neuroblasts towards the striatum
in R6/2 mice
We observed an increased number of neuroblasts in the
striatum adjacent to the SVZ. Quantification of DCX-
positive cells in the striatum revealed significantly higher
numbers in transgenic animals compared to WT (44.0 ±
28.1 in WT vs. 348.0 ± 237.7 in R6/2, p < 0.05, Fig. 2D).
These cells were predominantly located in close proxi-
mity to the SVZ with a decline of cell number away
f r o mt h eS V Z( F i g .2 A - C ) .T h i sm a yb ed u et on e u r o -
blasts migrating into the striatum. At distances greater
than 300 μm from the SVZ no DCX-immunopositive
neuroblasts were observed. To investigate if any new
cells obtained a mature neuronal phenotype in the stria-
tum, we investigated possible colocalization of bromo-
deoxyuridine (BrdU) with the mature neuronal marker
NeuN. In contrast to a previous study [20], we did not
observe BrdU/NeuN positive cells 4 weeks after BrdU
treatment. Moreover, as none of the DCX-positive stria-
tal cells colabeled with BrdU, we excluded that the lack
of striatal neurogenesis was due to a delayed maturation
longer than 4 weeks. These results in line with previous
studies [21,27] suggest that neuronal maturation of
newly generated cells is not present within the R6/2
striatum of 9-week old mice.
SVZ cell proliferation not affected in R6/2 mice
Proliferation in the SVZ was assessed by quantification
of cells labeled for proliferating cellular nuclear antigen
(PCNA). In accordance with previous data [21,28] the
number of proliferating cells in the SVZ of R6/2 animals
was unchanged compared to WT (8.49 ± 2.16 vs. 7.42 ±
3.11 (×10
3); Table 1, Fig. 3).
Decreased olfactory neurogenesis in HD mice
To study the amount of newly generated cells in the OB
which showed no structural abnormalities we analyzed
the number of BrdU-labeled cells in the GCL and in the
GLOM separately. For further investigation, the neuronal
identity of these newly generated cells was determined by
double-labeling with BrdU and NeuN. The total number
of newly generated BrdU/NeuN double-labeled cells was
determined to evaluate the effect of mutant htt on OB
neurogenesis. In the GCL we observed a significant 33%
reduction of BrdU-positive cells in R6/2 animals com-
pared to the WT group (46.8 ± 11.3 vs. 69.9 ± 15.1
(×10
3) ;p<0 . 0 5 ;T a b l e1 ,F i g .4 A - C ) .I nt h eG C Ln o
significant difference in neuronal differentiation was
detected (87% vs. 88%, p > 0.05; Table 1). Due to the
considerable reduction in newly generated cells this
resulted in a significant decrease in total BrdU/NeuN cell
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Page 2 of 11Figure 1 Expression pattern of mutant huntingtin in developing and mature neurons of the subventricular zone and the olfactory
bulb in R6/2 mice. SVZ derived neurons originate from dividing GFAP expressing cells ("stem cells”, B cells) that generate transit-amplifying cells
(C cells) which in turn give rise to neuroblasts (A cells). DCX-expressing neuroblasts migrate along the RMS to the olfactory bulb and
differentiate into different neuronal cell types in the GCL and the GLOM. Schematic representations of regions of adult neurogenesis in the SVZ/
olfactory bulb (E, adapted from (35)). Aggregates of mutant huntingtin (green) are absent in GFAP expressing SVZ stem cells (red, A), EGF-R
expressing transit-amplifying cells (red, B) and neuroblasts with DCX immunoreactivity (red, C), but appear in DARPP-32 positive mature neurons
of the adjacent striatum (red, D) of R6/2 mice. Moreover, neuroblasts of the RMS (F), the GCL (G) and the GLOM (H) do not show
immunoreactivity for mutant huntingtin. In contrast, aggregates of mutant huntingtin (green) were detected in mature, calretinin-expressing
neurons (red) of the GCL (I) and the GLOM (J) and in TH expressing neurons of the GLOM (red, K) of the olfactory bulb. Topro-3 (blue) was used
as counterstain for cell nuclei. Scale bar represents 20 μm.
Figure 2 R6/2 mice show increased migration of neuroblasts to the affected striatum compared to controls, without signs of
substantial striatal neurogenesis. Representative images of DCX-expressing neuroblasts in wild-type (WT; A) and R6/2 mice (R6/2; B), higher
magnification (from insert in B) of cells exhibiting heterogeneous morphologies (C): Some cells possess only short or no processes, some display
multiple well-developed processes characteristic of migrating cells. Arrows indicate migrating DCX positive cells leaving the SVZ. Quantification
of DCX-positive cells in the striatum of WT and R6/2 mice, predominantly in close proximity to the SVZ (D). Error bars represent SD, * indicates p
< 0.05. Scale bars represent 50 μm.
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Page 3 of 11numbers by 33% (40.7 ± 11.2 vs. 61.5 ± 15.1 (×10
3);
p < 0.05; Table 1; Fig. 5A-C).
In the GLOM, an even more pronounced 52% reduc-
tion of BrdU positive cells was measured in the R6/2
group compared to WT (4.8 ± 1.7 vs. 10.1 ± 3.9 (×10
3);
p < 0.01; Table 1, Fig. 4E-G). As in the GCL, differentia-
tion into a neuronal phenotype remained unchanged
(91% vs. 90%, p > 0.05; Table 1). The resulting number
of newly generated neurons was significantly reduced in
R6/2 mice compared to WT mice (4.4 ± 1.7 vs. 9.1 ±
3.5 (×10
3); p < 0.05; Table 1; Fig. 5D-F). Interestingly,
the fraction of BrdU-labeled newborn cells that also
expressed TH as a marker of a dopaminergic phenotype
was elevated in the R6/2 group (14 vs. 8%; p < 0.05;
T a b l e1 ;F i g .6 A ,B ) .T h i sl e dt ot h ef i n d i n gt h a tt h e
total number of newly generated dopaminergic GLOM
neurons was unchanged comparing R6/2 with WT
animals (656 ± 270 vs. 775 301; p > 0.05; Table 1).
Increased apoptosis in the OB of R6/2 mice
An increase of cell death has been described in the cor-
tex and the striatum of R6/2 mice [29]. To examine if
increased cell death is, at least in part, attributable to
the reduction in adult neurogenesis in the OB of these
HD animals, we performed immunohistochemical stain-
ing for terminal deoxynucleotidyltransferase-mediated
dUTP nick-end labeling (TUNEL)-positive cells in the
Table 1 Quantification of adult neurogenesis in the
olfactory bulb of wildtype and R6/2 mice
WT R6/2
Proliferation in the SVZ
PCNA (×10
3) 7.42 ± 3.11 8.49 ± 2.16
Neurogenesis in the OB granular cell layer
BrdU (×10
3) 69. 9 ± 15.1 46.8 ± 11.3
#
% BrdU/NeuN 88 ± 4 87 ± 3
BrdU × % BrdU/NeuN (×10
3) 61.5 ± 15.1 40.7 ± 11.2
#
Neurogenesis in the OB glomerular layer
BrdU (×10
3) 10.1 ± 3.9 4.8 ± 1.7
#
% BrdU/NeuN 90 ± 3 90 ± 6
BrdU × % BrdU/NeuN (×10
3) 9.1 ± 3.5 4.4 ± 1.7
#
% BrdU/TH 8 ± 2 14 ± 3
#
BrdU × % BrdU/TH 775 ± 301 656 ± 270
Morphological quantification of neurogenesis in the olfactory bulb of WT and
R6/2 mice comprises the following measures: total number of proliferating
cells in the subventricular zone (PCNA), total number of surviving newly
generated cells (BrdU), percentage of newly generated neurons (% BrdU/
NeuN) and total number of new neurons (BrdU × % BrdU/NeuN) in the
granular cell layer. For the glomerular layer, total number of surviving newly
generated cells (BrdU), percentage of newly generated neurons (% BrdU/
NeuN), percentage of newly generated dopaminergic neurons (% BrdU/TH),
total number of new neurons (BrdU × % BrdU/NeuN) and total number of
new dopaminergic neurons (BrdU × % BrdU/TH) are indicated. All measures
are expressed as mean ± SD.
# indicates significance comparing WT vs. R6/2
(p < 0.05).
Figure 3 Cell proliferation in the subventricular zone of the R6/2 HD animals is unchanged compared to WT controls.S t a i n i n gf o r
dividing cells with the cell cycle marker PCNA revealed no difference in the amount of stem and precursor cell proliferation in the SVZ of WT
(A) and R6/2 animals (B). Scale bar represents 20 μm.
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c e l l si nt h eG C Lo fR 6 / 2m i c ec o m p a r e dt oW Tm i c e
(Fig. 7A, B). This indicates that there is increased cell
death in the presence of mutant htt in the OB.
Discussion
Our data provide evidence that the expression of mutant
human htt with a CAG repeat expansion in transgenic
R6/2 mice is associated with a significant impairment in
the survival of newly generated neurons in the OB. We
demonstrated that both neurogenic regions of the OB -
the GCL and the GLOM - are severely affected in this
HD model. Interestingly, mutant htt could not be
detected in migrating neuroblasts of the SVZ/OB system
or in cells of earlier stages of neural development in the
SVZ (B and C cells). In contrast, numerous mature neu-
rons in the striatum and OB contain aggregates of
mutant htt. Thus, impaired adult neurogenesis in the
OB may be caused by non cell-autonomous mechan-
isms. Furthermore, it is noteworthy that it remains
unclear whether htt aggregates have a potential neuro-
protective or toxic function [30]. While there are recent
studies on aggregation kinetics of mutant htt and its dif-
ferent fragments [31,32], htt aggregration in developing
neurons remains elusive.
Adult neurogenesis in the SVZ/OB system is a highly
regulated process consisting of proliferation of neural pre-
cursor cells in the SVZ [33] and the subsequent matura-
tion into neuroblasts that migrate along the RMS to the
OB. While hippocampal neurogenesis is reduced in the
R6/2 mouse model [16,21,28], we confirmed previous stu-
dies that the proliferation of neural precursors in the SVZ
of R6/2 animals is unchanged [20,21]. Since mutant htt
severely affects the adjacent striatum, one potential repair
strategy to repopulate this region is to redirect SVZ-
derived neuroblasts to the striatum. Redirection of migrat-
ing neuroblasts to a lesion site was first described in an
animal model of cerebral ischemia [34]. In a model of
Parkinson’s disease, the combined application of growth
factors such as epidermal growth factor and fibroblast
Figure 4 Impaired survival of newly generated cells in the two neurogenic regions of the olfactory bulb in HD mice compared to
controls. Significant reduction of BrdU-labeled newly generated cells in the GCL and the GLOM 4 weeks after BrdU administration in R6/2 mice
compared to controls (C, G). Representative images of immunostainings for BrdU in the GCL (A, B) and the GLOM (E, F) of both groups.
Schematic representation of the OB areas analyzed (D). Error bars represent SD, * indicates p < 0.05. Scale bars represent 50 μm.
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Page 5 of 11Figure 5 The generation of new neurons in the neurogenic regions of the olfactory bulb is impaired in R6/2 animals compared to
controls. In the GCL the percentage of newly generated cells that differentiate into a neuronal phenotype is unchanged comparing WT and
R6/2 animals, as determined by double-labeling for BrdU and NeuN (A, B). Calculation of absolute numbers of surviving new neurons in the GCL
revealed significantly decreased neurogenesis in HD mice compared to controls (C). Analysis of differentiation in the GLOM demonstrated
unchanged neuronal differentiation in this region as well. Calculation of the total number of newly generated neurons in the GLOM showed a
reduction of more than 50% in R6/2 mice compared to WT controls (F). D and E show representative immunostainings for BrdU and NeuN in
the GLOM. Error bars represent SD, * indicates p < 0.05. Scale bars represent 20 μm.
Figure 6 Generation of dopaminergic neurons in the glomerular layer is less severely affected in HD mice compared to WT aminals.
Further analysis of the phenotype of newly generated neurons in the GLOM of the olfactory bulb revealed that the proportion of new
dopaminergic neurons (labeled for BrdU, NeuN and TH, A) was significantly increased in HD mice compared to controls (B). Scale bar represents
20 μm.
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Page 6 of 11growth factor 2 was sufficient to enhance migration of
neuroblasts to the striatum; however it did not result in
neuronal maturation [35]. In the present study, we
observed significantly more cells expressing the neuroblast
marker DCX in the striatum of R6/2 mice. These neuro-
blasts are localized in close proximity to the SVZ, indicat-
ing that these precursor cells may migrate as neuroblasts
into the diseased R6/2 striatum. Using colocalization of
BrdU with NeuN and of BrdU with DCX, we showed that
these neuroblasts do not acquire a mature neuronal phe-
notype. Striatal neurogenesis in HD animal models was
previously assessed with conflicting findings: The number
of DCX-expressing striatal cells was increased in quinolo-
nic acid-lesioned animals [36], and was even more pro-
nounced when neural and mesenchymal stem cells were
transplanted into the lesioned striatum [37]. On the other
hand, no alterations in DCX-expressing cells were
observed in untreated transgenic R6/2 mice compared to
WT controls [21]. Moreover, another study revealed the
presence of BrdU/NeuN double-positive cells in the stria-
tum of R6/2 animals [20], which we could not confirm
with our present findings. Furthermore, the intraventricu-
lar application of combined brain-derived neurotrophic
factor and Noggin was effective to generate significant
numbers of BrdU-labeled mature striatal neurons expres-
sing DARPP-32 and glutamic acid dehydrogenase-67
(GAD67) in R6/2 mice [27] indicating that additional neu-
rotrophic factors may be required for neuronal maturation
and survival in the striatum.
T h em a i nf o c u so ft h i ss t u d yw a st h ea n a l y s i so ft h e
survival of newborn neurons in the OB, the physiologi-
cal target region of SVZ-derived neural precursors. In
healthy animals, the first newly generated neuroblasts
arrive in the OB after two days: by 14 days the vast
majority reaches either their final destination or undergo
apoptosis [10]. Previously, a reduced number of BrdU-
labeled cells was shown in the RMS or the OB of R6/2
mice three or seven days after injection [20,38]. The
period of 28 days after the first BrdU application com-
prises nearly all labeled cells arriving in the OB. These
newly generated mature neurons usually integrate into
the existing network of the OB. We observed that num-
bers of newly generated OB neurons in the GCL and
GLOM were reduced by 33% and 50%, respectively, in
9-week old R6/2 animals. There are different potential
explanations for the reduced number of new neurons in
the OB. A decreased migration speed was proposed by a
recent study of RMS neuroblasts in R6/2 mice, because
of a shift in the number of BrdU-labeled cells from the
rostral to the caudal portion of the RMS [38]. Alterna-
tively, the reduction in OB neurogenesis may be related
to an increased cell death in HD mice. Previously, we
estimated a 50% cell survival rate of SVZ-derived newly
generated neurons in the adult OB [12]. Using TUNEL
staining in the GCL of R6/2 mice, we conclude that
increased cell death plays an important role in the
reduction of newborn OB neurons, comparable to other
brain areas of this HD animal model like the cortex and
the striatum, where increased cell death occurs [29]. We
hypothesize that progressive dysfunction is caused by
mutant htt rather in mature OB neurons and not in
DCX-positive neuroblasts. Moreover, mutant htt may
interfere with the integration of newly generated neu-
rons into the preexisting neural networks in the GCL
and GLOM, leading to increased cell death of develop-
ing OB neurons. Nevertheless, we can not rule out an
early toxic effect of mutant htt in monomeric or oligo-
meric form, as the used htt antibody mainly binds to htt
aggregates and is not able to distinguish different forms
of transgenic mutant htt.
w?>Further analysis of newly generated mature neu-
rons in the GLOM revealed a shift to a dopaminergic
phenotype. While most of the GLOM neurons are
GABAergic, a small portion of these cells co-expresses
TH [39]. Our finding that the percentage of TH-positive
new neurons was increased in HD animals, was
Figure 7 Increased cell death in the olfactory bulb of R6/2 mice. TUNEL staining of the GCL in the OB of WT and R6/2 animals shows an
increase of TUNEL-positive profiles in transgenic animals carrying the mutant huntingtin (B) compared to WT mice (A). Scale bar represents 50 μm.
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cells is less affected by mutant htt in comparison to
GABAergic neurons. This further supports that mutant
htt differentially affects various neuronal phenotypes dif-
ferentially in the HD brain [40].
Conclusion
Taken together, OB neurogenesis was severely affected in
the R6/2 animal model of HD. Unchanged SVZ prolifera-
tion and the absence of aggregates of mutant htt in
migrating neuroblasts suggest that the impact on new neu-
rons occurs at later stages of neural maturation. While
there are some indications of olfactory deficits in HD
patients [4,41], it remains unclear whether the reduced OB
neurogenesis may be related to this deficit. Moreover,
despite the supposed increase of neuroblast migration
from the SVZ into the striatum of R6/2 HD mice, the hos-
tile microenvironment of this region lacks the appropriate
signals to support mature neuronal differentiation.
Methods
Animals
Female B6CBAF1/J mice transplanted with ovaries from
female B6CBATg(Hdexon1) 62Gpb/1J mice (R6/2, [22])
were bred to male B6CBAF1/J mice. All animals were
obtained from Jackson Laboratories (Bar Harbor, USA).
Tail DNA was used for determining the CAG repeat
length in transgenic animals using a polymerase chain
reaction assay [22]. Female mice wild type (WT; n = 6)
a n dt r a n s g e n i c( R 6 / 2 ;n=6 )m i c ew e r ek e p ti nn o r m a l
light-dark cycle of 12 hours and had free access to food
and water. Labeling of replicating cells was performed
by intraperitoneal injection of the thymidine analogue
BrdU (Sigma, Steinheim, Germany) at 50 mg/kg of body
weight using a sterile solution of 10 mg/ml of BrdU dis-
solved in a 0.9% (w/v) NaCl solution. The BrdU injec-
tions were performed daily for 5 consecutive days at 5
weeks of age. Animals at 9 weeks of age were deeply
anaesthetized using a mixture of ketamine (20.38 mg/
ml), xylazine (5.38 mg/ml) and acepromazine (0.29 mg/
ml). Transcardial perfusion was performed with 0.9%
(w/v) NaCl solution, followed by a 4% paraformalde-
hyde, 0.1 M sodium phosphate solution (pH 7.4). Brains
were removed and post-fixed in the paraformaldehyde
solution overnight at 4°C. Tissues were then cryopro-
tected in a solution containing 30% (w/v) sucrose and
0.1 M sodium phosphate (pH 7.4). Brains were cut into
40 μm-thick sagittal sections using a sliding microtome
on dry ice. Sections were stored at - 20°C in cryoprotec-
tant solution (ethylene glycol, glycerol, 0.1 M phosphate
buffer pH 7.4, 1:1:2 by volume). All experiments were
carried out in accordance with the European Commu-
nities Council Directive of 24 November 1986 (86/609/
EEC) and were approved by the local governmental
commission for animal health.
Immunostaining
Immunostainings were conducted as described pre-
viously [16]. For BrdU and PCNA labeling, tissue was
pretreated with formamide and HCl to denature DNA.
Free-floating sections in Tris-buffered saline (TBS; 0.15
M NaCl, 0.1 M Tris-HCl, pH 7.5) were treated with
0.6% H2O2. Following extensive washes in TBS, sections
were blocked with a solution composed of TBS, 0.1%
Triton X-100 and 3% donkey serum (Sigma). This buffer
was also used during the incubation with antibodies.
Primary antibodies were applied overnight at 4°C. For
chromogenic immunodetection, sections were incubated
with biotin-conjugated species-specific secondary antibo-
dies followed by a peroxidase-avidin complex solution
from the Vectastain Elite ABC kit (Vector Laboratories,
Burlingame, USA). The peroxidase activity of immune
complexes was detected with a solution of TBS contain-
ing 0.25 mg/ml 3,3’-diaminobenzidine (Vector Labora-
tories), 0.01% (v/v) H2O2, and 0.04% (w/v) NiCl2.
Sections were put on Superfrost Plus slides (Menzel,
Braunschweig, Germany) and mounted in Neo Mount
(Merck, Darmstadt, Germany). For fluorescence immu-
nodetection, sections were washed extensively and incu-
bated with fluorochrome-conjugated species-specific
secondary antibodies for 2 h. Sections were put on slides
and mounted with Prolong Antifade reagent (Molecular
Probes, Eugene, USA). Light microscopy images were
obtained using a Leica microscope (Leica, Wetzlar,
Germany) equipped with a Spot™ digital camera (Diag-
nostic Instrument Inc, Sterling Heights, USA) and fluor-
escent images were obtained using a confocal scanning
laser microscope (Leica TCS-NT).
The following antibodies and final dilutions were used.
Primary antibodies: rat anti-BrdU (1:500; Oxford Bio-
technology, Oxford, UK), mouse anti-PCNA (1:500),
goat anti-DCX (1:200), goat anti-DARPP-32 (1:250; all
from Santa Cruz Biotechnology, Santa Cruz, USA), rab-
bit anti-GFAP (1:1000; Molecular Probes, Eugene, USA),
sheep anti-EGF-receptor (1:100, Upstate, Lake Placid,
USA), rabbit anti-calretinin (1:500; Swant, Bellinzona,
Switzerland), sheep anti-tyrosine hydroxylase (TH;
1:500), mouse anti-NeuN (1:500) and mouse anti-
mutant htt (1:500; all from Chemicon, Temecula, USA).
The mouse anti-huntingtin antibody MAB5374 detects
N-terminal mutant human htt with a repeat length >
82, in particular as htt aggregates, and much weaker
soluble forms, respectively. Secondary antibodies were
donkey-derived, species-specific and conjugated with
Alexa 488, Alexa 568, Alexa 660 (1:1000, Molecular
Probes) or biotin (1:500; Jackson Immuno Research,
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(1:2000; Molecular Probes) was diluted in TBS and
applied directly to the sections for 10 min.
To determine cell death in the OB, the TUNEL assay
was performed using the Apoptag In Situ Cell Death
Detection Kit (Intergene, Purchase, NY, USA). The
modified protocol for free floating sections was adminis-
tered which was previously described in detail [42]. For
chromogenic immunodetection, the identical protocol
using peroxidase activity as above was used.
Counting procedures and microscopy
All morphological analyses were conducted on blind-
coded slides. Every sixth section (240-μmi n t e r v a l )o f
one hemisphere was selected from each animal and pro-
cessed for immunohistochemistry. To analyze cell survi-
val after 4 weeks in the GCL and GLOM, the number
of BrdU-immunopositive cells was determined using the
counting procedure described by Williams and Rakic
[43]. Results were multiplied by 6 to obtain an estimate
of the total immunopositive cell numbers. Total num-
bers of labeled cells within the GLOM were counted
after determining the region of interest. BrdU-positive
cells within the GCL were estimated with the optical
dissector method [44] using a virtual counting frame of
50 × 50 μm spaced in a 300 × 300 μmc o u n t i n gg r i d .
Labeled cells which intersected the uppermost focal
plane (exclusion plane) or the lateral exclusion bound-
aries of the counting frame were not counted. The
stereology system finally calculated a precise estimation
of the total number of BrdU labeled cells within the
whole thickness of the OB as decribed previously [45].
To quantify striatal neuroblasts, DCX-positive cells were
exhaustively counted within the whole caudate/putamen
region bordered by the corpus callosum, the RMS, the
ventricle and the SVZ as well as the accumbens nucleus
[45]. Total numbers of PCNA labeled cells within the
SVZ were counted after determining the region of inter-
est. All counting procedures and measurements of refer-
ence volumes were conducted on a light microscope
(Leica) equipped with a semi-automatic stereology sys-
tem (Stereoinvestigator, MicroBrightField, Colchester,
USA) as previously described [45]. All extrapolations
were calculated for one hemisphere and should be
doubled to represent the total brain values.
To determine the frequency of neuronal differentiation
of newborn cells, every sixth brain section (240-μm
interval) was stained for BrdU and NeuN by immuno-
fluorescence and examined using a confocal laser micro-
s c o p e( L e i c aT C S - N T )e q u i p p e dw i t ha2 0 ×P L
FLUOTAR oil objective (0.75 numeric aperture) and a
40× PL APO oil objective (1.25 numeric aperture) and a
pinhole setting that corresponded to a focal plane of
2 μm. In the GCL, 100 BrdU-labeled cells per animal
were analyzed for neuronal differentiation. BrdU-positive
cells were characterized as solely BrdU-positive (new-
born cells) and BrdU+/NeuN+ double-positive cells
(newborn neurons). In the GLOM, 50 BrdU-positive
cells per animal were counted for neuronal differentia-
tion, identifying BrdU+/NeuN+ newborn neurons and
newly generated neurons with a dopaminergic pheno-
type (BrdU+/TH+). Further fluorescence images labeling
htt in combination with various other markers were also
obtained on the confocal scanning laser microscope
(40× PL APO oil objective, pinhole corresponding to a
focal plane of 2 μm).
Statistical analysis
The data are presented as mean values ± standard
deviations (SD). Student’s t-test was used to test for dif-
ferences in BrdU and DCX cell numbers, BrdU/NeuN
and BrdU/TH percentages, total number of BrdU
labeled neurons and total number of BrdU-labeled dopa-
minergic neurons. Statistical analysis was performed
using Prism (Prism Graph Pad Software, San Diego,
USA). Differences were considered significant at
p < 0.05, unless otherwise indicated.
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